ArticleFrontiers in oncology2025
Synchronous angiomyolipoma with epithelial cysts and clear cell renal cell carcinoma: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Angiomyolipoma with Epithelial Cysts (AMLEC) is a rare renal tumor that has been established as a separate pathological entity in recent years. Existing literature has focused on its histological origin, molecular features, and imaging characteristics. To our knowledge, this is the first reported case of AMLEC coexisting with clear cell renal cell carcinoma (ccRCC). Case presentation: A 37-year-old male presented with lumbar pain and persistent gross hematuria. Imaging revealed tumor rupture with hemorrhage, initially suggestive of cystic renal cell carcinoma. However, postoperative pathology and immunohistochemistry confirmed a diagnosis of AMLEC combined with ccRCC. Conclusion: AMLEC is a rare subtype of angiomyolipoma (AML) that typically lacks adipose tissue, with an epithelial component likely derived from dilated renal tubules. Its unique histological features and immunohistochemical staining are key to pathological diagnosis. This report also reviews prior cases of AMLEC and synchronous renal tumors, offering a valuable reference for clinical diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.